Clinical trials
TNF clinical trials
Below are recruiting tnf clinical trials, each written for real people, not researchers. We’re tracking 38 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06896305Recruiting
Adding a Special Diet to Anti-TNF Therapy for Crohn's and Colitis
This study tests whether adding a special diet (the Crohn's Disease Exclusion Diet) to standard anti-TNF medicine works better than the medicine alone for people with moderate to severe Crohn's disease or ulcerative colitis. You would be asked to follow a specific meal plan for several weeks while taking your regular medication.
Milan, MichiganAges 18 years+ - NCT07644117Recruiting
Personalized Anti-TNF Treatment for Inflammatory Bowel Disease
This trial tests a personalized approach to starting anti-TNF therapy—a common treatment for inflammatory bowel disease (IBD)—in patients who have never taken it before. The goal is to help doctors choose the right anti-TNF medication and dose based on each patient's individual characteristics.
Tel AvivAges 18 years+ - NCT06538870Recruiting
Dental implant healing and TNF-alpha blockers
This study looks at how dental implants heal in people who take TNF-alpha inhibitors (medicines that lower inflammation) compared to those who don't. It aims to see if the drug affects healing after implant surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05428488RecruitingPhase 3
Step-by-step treatment for rheumatoid arthritis with TNF medicine
This trial tests a step-by-step plan for treating rheumatoid arthritis when current medicines aren’t controlling the disease. It compares how well a targeted approach works by adjusting treatment for people who need a TNF inhibitor.
Montpellier, FranceAges 18 years+ - NCT07137598RecruitingPhase 2
A study of RO7790121 for moderate to severe rheumatoid arthritis
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
Avondale, ArizonaAges 18 years+ - NCT06712628Recruiting
Comparing how long people stay on upadacitinib vs TNF inhibitors for RA
This study compares how well people with rheumatoid arthritis stay on two types of medicines: upadacitinib (Rinvoq) and TNF inhibitors. It looks at real-world experiences in Germany to see if one medicine is more likely to be continued over time.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT04599621Recruiting
Testing treatment for heart pain with anxiety or depression
This trial looks at people who have coronary artery disease and unstable or certain stable chest-pain symptoms, especially when anxiety or depressive symptoms are also present. The goal is to see how the study approach helps heart symptoms when mental health symptoms occur at the same time.
SamarkandAges Any age - NCT05930613RecruitingPhase 3
Certolizumab for repeated embryo transfer pregnancy failure
This Phase 3 study tests certolizumab to help people with repeated embryo transfer failures achieve a clinical pregnancy. It may be an option if your infertility has no known cause and you meet the other study checks.
ParisAges 18–40 - NCT03839862Recruiting
Stool tests in people starting anti-TNF treatment
This study looks at stool (poop) samples to better understand therapy in people with spondyloarthritis (inflammatory joint conditions). You may be asked to provide stool samples right as you start anti-TNF treatment, which could help researchers tailor or improve care.
LundAges 18 years+ - NCT07802678RecruitingPhase 4
Stopping RA medicines in combination therapy
This study looks at whether people with rheumatoid arthritis who are stable on a TNF inhibitor plus another drug can safely stop the second drug. It aims to see if stopping the extra medicine keeps the disease under control and reduces side effects.
Nijmegen, GelderlandAges 18 years+ - NCT07686757Enrolling by invitationPhase 4
Study of mirikizumab for ulcerative colitis and Crohn's disease
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
Sun City, ArizonaAges 21 years+ - NCT06642207Recruiting
Comparing two biologic drugs for ankylosing spondylitis
This study compares two types of biologic drugs (IL-17 inhibitors vs. anti-TNF drugs) in people with ankylosing spondylitis (a form of arthritis affecting the spine) who have already tried standard treatments. The goal is to see which drug works better for controlling symptoms.
SohagAges 16–60 - NCT06585982Recruiting
Synbiotics for MAFLD: gut health and liver fat study
This trial tests whether taking a synbiotic (a mix of helpful bacteria and fiber) can improve insulin levels and reduce inflammation in people with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). It may help by changing the balance of bacteria in your gut.
Semarang, SemarangAges 25–55 - NCT06062875RecruitingPhase 2
Testing a drug for enlarged prostate symptoms
This trial tests whether a drug called adalimumab (a TNF blocker) can improve symptoms of an enlarged prostate. It is for men aged 45-80 with a large prostate and bothersome urinary symptoms who have not used this type of medication before.
Glenview, IllinoisAges 45–80 - NCT07554820RecruitingPhase 4
Heart Protection in Rheumatoid Arthritis With New Medications
This study compares two treatment approaches for people with active rheumatoid arthritis who also have heart disease risk factors. It tests whether a newer drug called tofacitinib, combined with cholesterol medication, can better protect the heart than traditional TNF-inhibitor treatments.
Lahore, Punjab ProvinceAges 50–85 - NCT07545317Recruiting
IL-23 Inhibitors for Active Crohn's Disease
This study follows patients with moderate-to-severe Crohn's disease who are starting a newer type of biologic medication called IL-23 inhibitors (guselkumab or risankizumab). Researchers want to understand how well these drugs work in real-world clinical practice and compare their effectiveness to other treatments.
Guangzhou, GuangdongAges 18–75 - NCT07529236Recruiting
How Children's Bowel Disease Responds After Switching IBD Medications
This study follows children who had to stop one type of IBD medicine (anti-TNFα) because it caused a skin condition called psoriasis, and were switched to a different medicine called ustekinumab. Researchers want to see how well their bowel disease is controlled with the new treatment.
Nice, FranceAges 6–17 - NCT07389772Enrolling by invitation
Immune markers in tooth retreatments for diabetics
This study tests whether different ways of activating the immune system during root canal retreatment affect levels of certain immune markers (TLR9, IL6, IL10, TNF-alfa) in people with type 2 diabetes. If you need a repeat root canal on a front tooth or lower premolar, you may be able to join.
Kirikkale, KırıkkaleAges 18–50 - NCT07380373Enrolling by invitation
Testing markers in body fluids for lung injury in children
This study looks at two substances in saliva and lung fluid—called IL-6 and TNF-α—in children with severe lung failure (ARDS) who are on a breathing machine. Measuring these markers may help doctors better understand the condition and guide treatment.
CairoAges 1–10 - NCT06653634RecruitingPhase 4
Optimizing treatment for kids with JIA in remission
This trial tests whether children with juvenile idiopathic arthritis (JIA) who have been doing well for over a year can safely reduce their medications. The goal is to find the best way to keep arthritis under control while avoiding unnecessary treatments.
BergenAges 2–17 - NCT07166315Recruiting
Comparing new treatments for arthritis of the spine or joints
This study looks at how well different newer medications work for people with axial spondyloarthritis or psoriatic arthritis. It focuses on those just starting treatment with bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor.
Bath, SomersetAges 18 years+ - NCT07170904Recruiting
Diet, inflammation, and zinc in women of childbearing age
This study looks at how diet, inflammation, zinc levels, and body composition relate to each other in women of different ethnic backgrounds living in Jakarta. It aims to understand nutrition and health patterns in this group.
Jakarta Pusat, DKI JakartaAges 19–49 - NCT03681652Recruiting
Study of recovery outcomes after Crohn’s surgery in children
This study looks at outcomes after children with Crohn’s disease have part of the bowel removed (ileo-cecal resection). It may help doctors improve post-surgery care, especially for preventing flare-ups in the months after surgery.
Petah Tikva, IsraelAges 6–18 - NCT04743518RecruitingPhase 4
How ulcerative colitis medicines affect blood vessel stiffness
This study looks at how common ulcerative colitis treatments (anti-TNF medicines, vedolizumab, or tofacitinib) change the health of your blood vessels. It may help doctors better understand cardiovascular risk in people with ulcerative colitis.
AmiensAges 18 years+
Hear when a new TNF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tnf?
- Yes. Clin2 currently lists 38 recruiting tnf studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tnf trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tnf trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.